Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia
- PMID: 38494070
- DOI: 10.1016/j.ajog.2024.03.012
Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia
Abstract
Background: Preeclampsia is characterized by maternal endothelial activation and placental dysfunction. Imbalance in maternal angiogenic and vasoactive factors has been linked to the pathophysiology. The contribution of the placenta as a source of these factors remains unclear. Furthermore, little is known about fetal angiogenic and vasoactive proteins and the relation between maternal and fetal levels.
Objective: We describe placental growth factor, soluble Fms-like tyrosine kinase 1, soluble endoglin, and endothelin 1-3 in 5 vessels in healthy pregnancies, early- and late-onset preeclampsia. Specifically, we aimed to (1) compare protein abundance in vessels at the maternal-fetal interface between early- and late-onset preeclampsia, and healthy pregnancies, (2) describe placental uptake and release of proteins, and (3) describe protein abundance in the maternal vs fetal circulations.
Study design: Samples were collected from the maternal radial artery, uterine vein and antecubital vein, and fetal umbilical vein and artery in 75 healthy and 37 preeclamptic mother-fetus pairs (including 19 early-onset preeclampsia and 18 late-onset preeclampsia), during scheduled cesarean delivery. This method allows estimation of placental release and uptake of proteins by calculation of venoarterial differences on each side of the placenta. The microarray-based SomaScan assay quantified the proteins.
Results: The abundance of soluble Fms-like tyrosine kinase 1 and endothelin 1 was higher in the maternal vessels in preeclampsia than in healthy pregnancies, with the highest abundance in early-onset preeclampsia. Placental growth factor was lower in the maternal vessels in early-onset preeclampsia than in both healthy and late-onset preeclampsia. Maternal endothelin 2 was higher in preeclampsia, with late-onset preeclampsia having the highest abundance. Our model confirmed placental release of placental growth factor and soluble Fms-like tyrosine kinase 1 to the maternal circulation in all groups. The placenta released soluble Fms-like tyrosine kinase 1 into the fetal circulation in healthy and late-onset preeclampsia pregnancies. Fetal endothelin 1 and soluble Fms-like tyrosine kinase 1 were higher in early-onset preeclampsia, whereas soluble endoglin and endothelin 3 were lower in both preeclampsia groups than healthy controls. Across groups, abundances of placental growth factor, soluble Fms-like tyrosine kinase 1, and endothelin 3 were higher in the maternal artery than the fetal umbilical vein, whereas endothelin 2 was lower.
Conclusion: An increasing abundance of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 across the groups healthy, late-onset preeclampsia and early-onset combined with a positive correlation may suggest that these proteins are associated with the pathophysiology and severity of the disease. Elevated endothelin 1 in the fetal circulation in early-onset preeclampsia represents a novel finding. The long-term effects of altered protein abundance in preeclampsia on fetal development and health remain unknown. Further investigation of these proteins' involvement in the pathophysiology and as treatment targets is warranted.
Keywords: angiogenesis; endoglin; endothelin; placenta; placental growth factor; preeclampsia; pregnancy; soluble Fms-like tyrosine kinase 1; vasoconstriction.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Similar articles
-
In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5. Am J Obstet Gynecol. 2016. PMID: 27503620
-
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.Am J Obstet Gynecol. 2016 Mar;214(3):356.e1-356.e15. doi: 10.1016/j.ajog.2015.12.019. Epub 2015 Dec 22. Am J Obstet Gynecol. 2016. PMID: 26721779
-
Maternal vascular-placental axis in the third trimester in women with gestational diabetes mellitus, hypertensive disorders, and unaffected pregnancies.Am J Obstet Gynecol. 2025 May;232(5):489.e1-489.e11. doi: 10.1016/j.ajog.2024.08.045. Epub 2024 Aug 30. Am J Obstet Gynecol. 2025. PMID: 39218286
-
Expert review: preeclampsia Type I and Type II.Am J Obstet Gynecol MFM. 2023 Dec;5(12):101203. doi: 10.1016/j.ajogmf.2023.101203. Epub 2023 Oct 21. Am J Obstet Gynecol MFM. 2023. PMID: 37871693 Review.
-
An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.Am J Obstet Gynecol. 2022 Feb;226(2S):S963-S972. doi: 10.1016/j.ajog.2020.10.023. Epub 2021 Mar 9. Am J Obstet Gynecol. 2022. PMID: 33712272 Review.
Cited by
-
The role of 1-Deoxysphingolipids and Polyamines in the pathogenesis of placental syndrome.BMC Pregnancy Childbirth. 2025 Jan 22;25(1):51. doi: 10.1186/s12884-025-07175-1. BMC Pregnancy Childbirth. 2025. PMID: 39844083 Free PMC article.
-
Practical Considerations Concerning Preeclampsia Subgroups.J Clin Med. 2025 Apr 6;14(7):2498. doi: 10.3390/jcm14072498. J Clin Med. 2025. PMID: 40217948 Free PMC article. Review.
-
ORAI1, FGF23, PP13, palladin, and supervillin as potential biomarkers in late-onset pre-eclampsia: a comparative study in maternal and cord blood.BMC Pregnancy Childbirth. 2025 Jul 24;25(1):786. doi: 10.1186/s12884-025-07890-9. BMC Pregnancy Childbirth. 2025. PMID: 40707903 Free PMC article.
-
Prediction of late-onset preeclampsia using plasma proteomics: a longitudinal multi-cohort study.Sci Rep. 2024 Dec 28;14(1):30813. doi: 10.1038/s41598-024-81277-2. Sci Rep. 2024. PMID: 39730472 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous